AGX51, a first-in-class pan-Id (inhibitors of DNA-binding/differentiation proteins) antagonist and degrader, inhibits the Id1-E47 interaction, leading to ubiquitin-mediated degradation of Ids, cell growth arrest, and reduces viability, also inhibits pathologic ocular neovascularization.